Renal Hypophosphatemic Rickets: Growth and Mineral Metabolism After Treatment With Calcitriol (1,25-Dihydroxyvitamin D3) and Phosphate Supplementation

Noboru Tsuru, James C.M. Chan, Vernon Chinchilli

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To delineate the mineral metabolism of renal hypophosphatemic rickets and to update progress in linear growth after calcitriol (1,25-dihydroxyvitamin D3) therapy, the medical records of 19 patients were examined retrospectively from January 1978 through December 1985. With a mean (± SD) follow-up period of 42.0±5.4 months after calcitriol had been administered for at least 12 months, the growth measurements were as follows: the percentile weight (mean ± SD) remained unchanged, with the initial being 12.3%±17.3% and the final being 15.3%±18.6%, and the length/height percentiles were -2.7%±5.9% and -2.4%±4.4%. The growth velocity index showed a significant improvement from mean values of 61.7% (at age 2 years) to mean values of 101.2% (at age 11.2 years). Serum phosphate concentrations rose from the initial value of 2.9±0.6 to 3.5±0.8 mg/dL (0.9±0.2 to 1.1±0.3 mmol/L). The effects of calcitriol on renal function were tested by creatinine clearance values, which were 127±22 mL/min/1.73 m2 (2.12±0.37 mL/s/1.73m2) at the conclusion of the study, compared with 128±25 mL/min/1.73 m2 (2.13±0.41 mL/s/1.73m.2) obtained at the initiation of calcitriol therapy. We conclude that calcitriol treatment of renal hypophosphatemic rickets in children results in improvement of growth velocity and serum phosphate concentration without deterioration of renal function.

Original languageEnglish (US)
Pages (from-to)108-110
Number of pages3
JournalAmerican Journal of Diseases of Children
Volume141
Issue number1
DOIs
StatePublished - Jan 1 1987

Fingerprint

Hypophosphatemic Rickets
Chronic Kidney Disease-Mineral and Bone Disorder
Calcitriol
Minerals
Phosphates
Growth
Therapeutics
Kidney
Serum
Medical Records
Creatinine
Weights and Measures

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{4c95c8951f8b4de78da75c1f91fac189,
title = "Renal Hypophosphatemic Rickets: Growth and Mineral Metabolism After Treatment With Calcitriol (1,25-Dihydroxyvitamin D3) and Phosphate Supplementation",
abstract = "To delineate the mineral metabolism of renal hypophosphatemic rickets and to update progress in linear growth after calcitriol (1,25-dihydroxyvitamin D3) therapy, the medical records of 19 patients were examined retrospectively from January 1978 through December 1985. With a mean (± SD) follow-up period of 42.0±5.4 months after calcitriol had been administered for at least 12 months, the growth measurements were as follows: the percentile weight (mean ± SD) remained unchanged, with the initial being 12.3{\%}±17.3{\%} and the final being 15.3{\%}±18.6{\%}, and the length/height percentiles were -2.7{\%}±5.9{\%} and -2.4{\%}±4.4{\%}. The growth velocity index showed a significant improvement from mean values of 61.7{\%} (at age 2 years) to mean values of 101.2{\%} (at age 11.2 years). Serum phosphate concentrations rose from the initial value of 2.9±0.6 to 3.5±0.8 mg/dL (0.9±0.2 to 1.1±0.3 mmol/L). The effects of calcitriol on renal function were tested by creatinine clearance values, which were 127±22 mL/min/1.73 m2 (2.12±0.37 mL/s/1.73m2) at the conclusion of the study, compared with 128±25 mL/min/1.73 m2 (2.13±0.41 mL/s/1.73m.2) obtained at the initiation of calcitriol therapy. We conclude that calcitriol treatment of renal hypophosphatemic rickets in children results in improvement of growth velocity and serum phosphate concentration without deterioration of renal function.",
author = "Noboru Tsuru and Chan, {James C.M.} and Vernon Chinchilli",
year = "1987",
month = "1",
day = "1",
doi = "10.1001/archpedi.1987.04460010108039",
language = "English (US)",
volume = "141",
pages = "108--110",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Renal Hypophosphatemic Rickets

T2 - Growth and Mineral Metabolism After Treatment With Calcitriol (1,25-Dihydroxyvitamin D3) and Phosphate Supplementation

AU - Tsuru, Noboru

AU - Chan, James C.M.

AU - Chinchilli, Vernon

PY - 1987/1/1

Y1 - 1987/1/1

N2 - To delineate the mineral metabolism of renal hypophosphatemic rickets and to update progress in linear growth after calcitriol (1,25-dihydroxyvitamin D3) therapy, the medical records of 19 patients were examined retrospectively from January 1978 through December 1985. With a mean (± SD) follow-up period of 42.0±5.4 months after calcitriol had been administered for at least 12 months, the growth measurements were as follows: the percentile weight (mean ± SD) remained unchanged, with the initial being 12.3%±17.3% and the final being 15.3%±18.6%, and the length/height percentiles were -2.7%±5.9% and -2.4%±4.4%. The growth velocity index showed a significant improvement from mean values of 61.7% (at age 2 years) to mean values of 101.2% (at age 11.2 years). Serum phosphate concentrations rose from the initial value of 2.9±0.6 to 3.5±0.8 mg/dL (0.9±0.2 to 1.1±0.3 mmol/L). The effects of calcitriol on renal function were tested by creatinine clearance values, which were 127±22 mL/min/1.73 m2 (2.12±0.37 mL/s/1.73m2) at the conclusion of the study, compared with 128±25 mL/min/1.73 m2 (2.13±0.41 mL/s/1.73m.2) obtained at the initiation of calcitriol therapy. We conclude that calcitriol treatment of renal hypophosphatemic rickets in children results in improvement of growth velocity and serum phosphate concentration without deterioration of renal function.

AB - To delineate the mineral metabolism of renal hypophosphatemic rickets and to update progress in linear growth after calcitriol (1,25-dihydroxyvitamin D3) therapy, the medical records of 19 patients were examined retrospectively from January 1978 through December 1985. With a mean (± SD) follow-up period of 42.0±5.4 months after calcitriol had been administered for at least 12 months, the growth measurements were as follows: the percentile weight (mean ± SD) remained unchanged, with the initial being 12.3%±17.3% and the final being 15.3%±18.6%, and the length/height percentiles were -2.7%±5.9% and -2.4%±4.4%. The growth velocity index showed a significant improvement from mean values of 61.7% (at age 2 years) to mean values of 101.2% (at age 11.2 years). Serum phosphate concentrations rose from the initial value of 2.9±0.6 to 3.5±0.8 mg/dL (0.9±0.2 to 1.1±0.3 mmol/L). The effects of calcitriol on renal function were tested by creatinine clearance values, which were 127±22 mL/min/1.73 m2 (2.12±0.37 mL/s/1.73m2) at the conclusion of the study, compared with 128±25 mL/min/1.73 m2 (2.13±0.41 mL/s/1.73m.2) obtained at the initiation of calcitriol therapy. We conclude that calcitriol treatment of renal hypophosphatemic rickets in children results in improvement of growth velocity and serum phosphate concentration without deterioration of renal function.

UR - http://www.scopus.com/inward/record.url?scp=0023230466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023230466&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1987.04460010108039

DO - 10.1001/archpedi.1987.04460010108039

M3 - Article

C2 - 3788870

AN - SCOPUS:0023230466

VL - 141

SP - 108

EP - 110

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 1

ER -